The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer

CME Available: https://auau.auanet.org/node/39542

Release Date: December, 2023

Expiration Date: December, 2024

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Identify the rationale behind using adjuvant therapies in high-risk non-metastatic kidney cancer and the goals of adjuvant treatment.

2. Describe the adjuvant therapies that have been investigated to date for high-risk non-metastatic kidney cancer, including targeted therapies, immunotherapies, and combination approaches.

3. Discuss the challenges and limitations associated with adjuvant therapy trials in high-risk non-metastatic kidney cancer, such as patient selection, trial design, and long-term follow-up.

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 

Lantheus Medical Imaging

Merck & Co., Inc.